Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1997 2
1998 2
1999 2
2000 1
2001 3
2002 1
2004 3
2005 2
2006 2
2007 1
2008 2
2009 2
2010 5
2011 2
2012 3
2013 6
2014 6
2015 2
2016 2
2017 3
2018 5
2020 1
2021 2
2023 3
2024 5
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.
Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A, Baudin E, Berikova E, Berry C, Bonnet M, Cellamare M, Chavan V, Cox V, Dakenova Z, de Jong BC, Ferlazzo G, Karabayev A, Kirakosyan O, Kiria N, Kunda M, Lachenal N, Lecca L, McIlleron H, Motta I, Toscano SM, Mushtaque H, Nahid P, Oyewusi L, Panda S, Patil S, Phillips PPJ, Ruiz J, Salahuddin N, Garavito ES, Seung KJ, Ticona E, Trippa L, Vasquez DEV, Wasserman S, Rich ML, Varaine F, Mitnick CD; endTB Clinical Trial Team. Guglielmetti L, et al. N Engl J Med. 2025 Jan 30;392(5):468-482. doi: 10.1056/NEJMoa2400327. N Engl J Med. 2025. PMID: 39879593 Free PMC article. Clinical Trial.
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.
Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Ali MH, Amjad S, Kamal F, Abubakirov A, Ardizzoni E, Baudin E, Bektassov S, Berry C, Bonnet M, Chavan V, Coutisson S, Dakenova Z, de Jong BC, Dinh LV, Ferlazzo G, Kirakosyan O, Lachenal N, Lecca L, McIlleron H, Mikanda KK, Mucching-Toscano S, Mulders W, Mushtaque H, Nahid P, Nguyen DV, Nguyen NV, Oyewusi L, Motta I, Panda S, Patil S, Pham TH, Phan DT, Phan HTT, Phillips PPJ, Ruiz J, Rupasinghe P, Salahuddin N, Sanchez-Garavito E, Seung KJ, Asfaw MT, Vargas Vasquez D, Rich ML, Varaine F, Mitnick CD; endTB-Q Clinical Trial Team. Guglielmetti L, et al. Lancet Respir Med. 2025 Sep;13(9):809-820. doi: 10.1016/S2213-2600(25)00194-8. Epub 2025 Jul 16. Lancet Respir Med. 2025. PMID: 40683298 Free article. Clinical Trial.
Position of the international forum of internal medicine on habits, lifestyle changes and a healthy environment for the prevention of cardiovascular diseases.
Sabio R, Valdez P, Nachón MN, Arias C, Nitsch Montiel C, Penny E, Melgar Cuellar F, Araya Fonseca C, Montúfar Guardado R, Cotignola Á, Odzak A, Franchella J, Bisso A, Duran M, Palencia Vizcarra R, Gómez Huelgas R, Rodríguez W, Milione H, Parodi R, Buchaca Faxas E, Rojas Orellana L, Fortuna Peralta ML, Coral Cristaldo C, Ortellado J, Diez Manglano J, Barrios J, Jiménez MC, Gutiérrez Tudela J, Bruno G, Contreras Mónchez J, Payaslián S, Pollán J, Hernández H, Vaucher A, Betancourt I, Codina H, Celauro H, Cortese S, Risso M, Puello H, Casariego E, Díaz Salazar L, García Peña R, Indacochea-Cáceda S, García-Carrión L, Murillo Salvatierra E, Mirofsky M, Andrade G, Savia A, Canda P, Cárdenas A, Rodríguez Hurtado D, Chimeno Viñas M, Patiño M, Gómez Mendoza R, Arbo G, Romano HJ, Sánchez Cabezas A, Abuabara Turbay Y, Hiza R, Campos L, Do Patrocinio Tenorio Nunes M, Santos L, Salazar Matos V, Espinosa T, González Ruiz Díaz J, Carrasco S, Romani A, Escalera L, Palencia Díaz R, Giaccaglia G, Galarza Nuñez J, Román Sánchez P, Costanzo M, Garay Tamara S, Rodriguez García J, Bellini O, Ruiz Cantero A, Cámera L, Serra Valdés M, Ledesma R, Blanco Aspiazu M, Mejía Terrero A, Arango Álvarez JJ, Cárcam… See abstract for full author list ➔ Sabio R, et al. Among authors: galarza c. Medicina (B Aires). 2023 Jan 10;83 Suppl 1:1-53. Medicina (B Aires). 2023. PMID: 38290428 Free article. English.
Skin diseases in the Peruvian Amazonia.
Gutierrez EL, Galarza C, Ramos W, Tello M, Jiménez G, Ronceros G, Chía H, Hurtado J, Ortega-Loayza AG. Gutierrez EL, et al. Among authors: galarza c. Int J Dermatol. 2010 Jul;49(7):794-800. doi: 10.1111/j.1365-4632.2010.04473.x. Int J Dermatol. 2010. PMID: 20618500
Meal-induced blood pressure fall in patients with isolated morning hypertension.
Barochiner J, Alfie J, Aparicio LS, Cuffaro PE, Rada MA, Morales MS, Galarza CR, Marín MJ, Waisman GD. Barochiner J, et al. Among authors: galarza cr. Clin Exp Hypertens. 2015;37(5):364-8. doi: 10.3109/10641963.2014.972564. Epub 2014 Oct 27. Clin Exp Hypertens. 2015. PMID: 25347162 Free article.
Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire.
Haraoui B, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Codreanu C, Da Silva JP, de Wit M, Dougados M, Durez P, Emery P, Fonseca JE, Gibofsky A, Gomez-Reino J, Graninger W, Hamuryudan V, Jannaut Peña MJ, Kalden J, Kvien TK, Laurindo I, Martin-Mola E, Montecucco C, Santos Moreno P, Pavelka K, Poor G, Cardiel MH, Stanislawska-Biernat E, Takeuchi T, van der Heijde D; Treat to Target Taskforce. Haraoui B, et al. Ann Rheum Dis. 2011 Nov;70(11):1999-2002. doi: 10.1136/ard.2011.154179. Epub 2011 Jul 29. Ann Rheum Dis. 2011. PMID: 21803747 Free PMC article.
68 results